Status:
COMPLETED
An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Schizophrenia
Metabolic Syndrome X
Eligibility:
All Genders
18-55 years
Brief Summary
The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.
Detailed Description
Sampling Method Details: Group of patients using the same atypical anti-psychotic.
Eligibility Criteria
Inclusion
- Female and male patients diagnosed as schizophrenia by the Diagnostic and Statistical Manual of Mental Disorders.
- Age between 18-45 years
- Patients who started atypical antipsychotic drug treatment or patients who switched from the previous conventional or atypical antipsychotic treatment to another atypical antipsychotic drug treatment by the decision of their physicians.
Exclusion
- Patients who are pregnant or considering pregnancy.
Key Trial Info
Start Date :
October 23 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2008
Estimated Enrollment :
328 Patients enrolled
Trial Details
Trial ID
NCT00448630
Start Date
October 23 2007
End Date
July 30 2008
Last Update
May 3 2022
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Adana Psychiatry and Neurology Hospital
Kurttepe, Adana, Turkey (Türkiye), 01360
2
Pfizer Investigational Site
Kurttepe, Adana, Turkey (Türkiye), 01360
3
Adana Psychiatry and Neurology Hospital
Adana, Turkey (Türkiye)
4
Cukurova University Scool of Medicine
Adana, Turkey (Türkiye)